Myfortic Related Published Studies
Well-designed clinical trials related to Myfortic (Mycophenolic Acid)
Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. [2011.08.29]
How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation. [2011.04]
Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. [2011.03]
Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. [2011.02.15]
The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. [2011.02]
Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. [2010.12]
Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. [2010.06]
Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the opticept trial. [2010.04]
Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. [2010.03.15]
The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. [2010.01]
Optimal mycophenolic acid and mycophenolic acid glucuronide levels at the early period after kidney transplantation are the key contributors to improving long-term outcomes. [2009.10]
Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. [2009.10]
Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. [2009.02]
Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. [2009]
AcylMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840G>A Gene Polymorphism. [2008.08]
Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. [2007.07]
Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. [2007.03]
Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. [2007.01]
Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. [2006.08]
Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium. [2006.08]
Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. [2005.12]
Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. [2005.09]
Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. [2005.07]
Therapeutic mycophenolic acid monitoring by means of limited sampling strategy in orthotopic heart transplant patients. [2005.06]
Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, open, prospective controlled study. [2005.03]
Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. [2004.06]
Mycophenolic acid concentrations are associated with cardiac allograft rejection. [2000.11]
Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. [2000.05]
Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. [1999.11.27]
Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. [1996.09.15]
Well-designed clinical trials possibly related to Myfortic (Mycophenolic Acid)
Phase II trial of methotrexate in myasthenia gravis. [2012]
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results
of a prematurely terminated trial. [2012]
Efficacy and safety of rituximab in patients with active proliferative lupus
nephritis: the Lupus Nephritis Assessment with Rituximab study. [2012]
Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. [2011.09.15]
Randomized trial of immunosuppressive regimens in renal transplantation. [2011.09]
Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. [2011.08.27]
Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. [2011.07.27]
Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. [2011.07.15]
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. [2011.07]
Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. [2011.06.15]
Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response. [2011.06]
Therapeutic approaches in myositis. [2011.06]
Cyclophosphamide and lupus nephritis: when, how, for how long? [2011.06]
Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. [2011.06]
Alemtuzumab induction in renal transplantation. [2011.05.19]
Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. [2011.05]
Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. [2011.04.15]
Steroid avoidance reduce the cost of morbidities after live-donor renal allotransplants: a prospective, randomized, controlled study. [2011.04]
Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. [2011.04]
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. [2011.04]
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. [2011.03.05]
Single-dose, two-way crossover, bioequivalence study of Mycophenolate mofetil 500 mg tablet under fasting conditions in healthy male subjects. [2011.03]
Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. [2011.03]
[Bullous pemphigoid: a review]. [2011.03]
Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. [2011.03]
Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. [2011.03]
A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. [2011.03]
Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. [2011.03]
Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients. [2011.03]
Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial. [2011.03]
Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. [2011.03]
Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. [2011.02.27]
Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study. [2011.02]
The effects of early rapid corticosteroid reduction on cell-mediated immunity in kidney transplant recipients. [2011.01.15]
The treatment of relapse in adults with minimal change nephrotic syndrome: myths and facts. [2011.01]
Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. [2011.01]
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. [2011.01]
The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. [2011]
Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. [2011]
Early termination of a trial of mycophenolate mofetil for treatment of
interstitial cystitis/painful bladder syndrome: lessons learned. [2011]
Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. [2010.12.01]
Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial. [2010.12]
Cyclosporine and mycophenolate mofetil 48 hours before renal transplantation enables the use of low cyclosporine doses and achieves better graft function. [2010.12]
The role of generics in kidney transplant: mycophenolate mofetil 500 versus mycophenolate: 2-year results. [2010.12]
Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. [2010.12]
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. [2010.12]
Cytomegalovirus risk factors in renal transplantation with modern immunosuppression. [2010.12]
Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis. [2010.12]
Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. [2010.11]
Histological progression of chronic renal allograft injury comparing sirolimus and mycophenolate mofetil-based protocols. A single-center, prospective, randomized, controlled study. [2010.11]
Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. [2010.11]
Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. [2010.10.27]
Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. [2010.10]
Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. [2010.10]
Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. [2010.10]
Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. [2010.10]
Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. [2010.09]
A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. [2010.09]
Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. [2010.08]
Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. [2010.08]
Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. [2010.08]
Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. [2010.07.27]
The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. [2010.07]
High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. [2010.07]
Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. [2010.07]
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. [2010.07]
Randomized trial of early corticosteroid reduction vs. regular-dose corticosteroid maintenance in combination with tacrolimus and mycophenolate mofetil in living donor kidney transplant recipients: the Brazilian CORRETA trial. [2010.07]
Acute rejection in low-toxicity regimens: clinical impact and risk factors in the Symphony study. [2010.07]
Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. [2010.06.27]
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. [2010.06.27]
Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? [2010.06]
|
